ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy
- PMID: 21062153
- DOI: 10.2217/fon.10.122
ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy
Abstract
ASA404 (5,6-dimethylxanthenone-4-acetic acid) was developed as an analogue of flavone acetic acid and found to induce hemorrhagic necrosis of experimental tumors. ASA404 simultaneously targets at least two cell types - vascular endothelial cells and macrophages - within the tumor microenvironment. In murine tumors, ASA404 induces coordinated decreases in tumor blood flow, increases in vascular permeability and increases in vascular endothelial apoptosis, all occurring within 1 h of administration. Over a slightly longer time scale, ASA404 induces an increase in tumor concentrations of TNF and a number of other cytokines. Phase I clinical trials confirmed its vascular effects in humans and Phase II trials demonstrated its activity in combination with the cytotoxic agents carboplatin and paclitaxel. While the molecular target of its action is not yet identified, current results suggest that ASA404 has the potential to augment the antitumor effects of other agents in cancer treatment. Studies of changes in tumor tissue following treatment with ASA404 either alone or combined and other agents will provide new insights into the dynamics of the tumor microenvironment.
Similar articles
-
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.Expert Opin Investig Drugs. 2010 Feb;19(2):295-304. doi: 10.1517/13543780903540214. Expert Opin Investig Drugs. 2010. PMID: 20050824
-
Temporal aspects of the action of ASA404 (vadimezan; DMXAA).Expert Opin Investig Drugs. 2010 Nov;19(11):1413-25. doi: 10.1517/13543784.2010.529128. Expert Opin Investig Drugs. 2010. PMID: 20964495 Free PMC article. Review.
-
Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.Cancer. 2010 Apr 15;116(8):1859-71. doi: 10.1002/cncr.24975. Cancer. 2010. PMID: 20166210 Review.
-
Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.Clin Lung Cancer. 2011 Mar;12(2):81-6. doi: 10.1016/j.cllc.2011.03.001. Epub 2011 Apr 8. Clin Lung Cancer. 2011. PMID: 21550553 Review.
-
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.Lung Cancer. 2009 Aug;65(2):192-7. doi: 10.1016/j.lungcan.2009.03.027. Epub 2009 May 5. Lung Cancer. 2009. PMID: 19409645 Clinical Trial.
Cited by
-
TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types.Cancer Cell. 2012 Feb 14;21(2):212-26. doi: 10.1016/j.ccr.2012.01.004. Cancer Cell. 2012. PMID: 22340594 Free PMC article.
-
A cooperative polymeric platform for tumor-targeted drug delivery.Chem Sci. 2016 Jan 1;7(1):728-736. doi: 10.1039/c5sc01698c. Epub 2015 Oct 26. Chem Sci. 2016. PMID: 28791115 Free PMC article.
-
Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?J Thorac Dis. 2010 Dec;2(4):189-91. doi: 10.3978/j.issn.2072-1439.2010.11.9. J Thorac Dis. 2010. PMID: 22263043 Free PMC article. No abstract available.
-
The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model.Front Immunol. 2022 Nov 18;13:969678. doi: 10.3389/fimmu.2022.969678. eCollection 2022. Front Immunol. 2022. PMID: 36466911 Free PMC article.
-
Carboxyxanthones: Bioactive Agents and Molecular Scaffold for Synthesis of Analogues and Derivatives.Molecules. 2019 Jan 5;24(1):180. doi: 10.3390/molecules24010180. Molecules. 2019. PMID: 30621303 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources